Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete …